Triều Tiên: Việc tiếp tục duy trì đàm phán phụ thuộc vào Mỹ

Nhà đàm phán hàng đầu của Triều Tiên Kim Myong-gil ngày 7/10 tuyên bố, việc nước này và Mỹ có tiến tới tổ chức các cuộc đàm phán phi hạt nhân bổ sung hay không phụ thuộc vào Mỹ.

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

Bình luận

Xin vui lòng gõ tiếng Việt có dấu

Tin cùng chuyên mục

Hy vọng mới trong điều trị ung thư tuyến tụy

Hy vọng mới trong điều trị ung thư tuyến tụy

Thế giới
(Baothanhhoa.vn) - Một loại thuốc thử nghiệm có tên Daraxonrasib đang mở ra hy vọng mới trong điều trị ung thư tuyến tụy, sau khi kết quả nghiên cứu công bố trên tạp chí y khoa New England Journal of Medicine cho thấy thuốc có thể giúp kéo dài gấp đôi thời gian sống...
Chứng nhận tín nhiệm mạng
Việt Long Phần mềm tòa soạn
hội tụ thông minh